About Sequella

Founded in 1997, Sequella develops products to improve diagnosis and treatment of infectious diseases that pose serious risk to public health and have both significant market opportunities and clear commercialization pathways. The company’s growth strategy capitalizes on the experience of its executive management and scientific talent to advance new compounds with best-in-class potential from the bench to the clinic -- ultimately delivering these products to patients through strategic partnerships and alliances.